Klinikum Stuttgart

This research area focuses on neoplasms in children, with a strong emphasis on high-risk neuroblastoma. The trials are designed to improve treatment outcomes by evaluating better ways to combine chemotherapy, radiotherapy, and immunotherapy for young patients with difficult-to-treat disease.

• Studying treatment strategies for high-risk neuroblastoma after initial therapy response
• Comparing approaches that use high-dose chemotherapy and radiotherapy to improve survival
• Assessing chemoimmunotherapy for patients with persistent metastatic disease

Overall, the work at this site aims to refine pediatric cancer care by testing more effective treatment combinations and improving outcomes for children with aggressive tumors.

This trial area explores how the immune system can be modulated in living donor kidney transplantation. The main goal is to evaluate whether donor-derived modified immune cells can support better transplant acceptance and promote a tolerance-like response compared with standard treatment.

• Investigating kidney transplantation outcomes in recipients of living donor organs
• Testing whether immune suppression can be tailored to encourage operational tolerance
• Comparing a new cell-based approach with standard-of-care therapy

At Klinikum Stuttgart, this research reflects a broader effort to improve transplant success while reducing the need for long-term immune suppression.